Connection

PETER HOTEZ to Leishmaniasis, Cutaneous

This is a "connection" page, showing publications PETER HOTEZ has written about Leishmaniasis, Cutaneous.
Connection Strength

0.805
  1. Cutaneous leishmaniasis and co-morbid major depressive disorder: A systematic review with burden estimates. PLoS Negl Trop Dis. 2019 02; 13(2):e0007092.
    View in: PubMed
    Score: 0.147
  2. A new perspective on cutaneous leishmaniasis-Implications for global prevalence and burden of disease estimates. PLoS Negl Trop Dis. 2017 08; 11(8):e0005739.
    View in: PubMed
    Score: 0.132
  3. Expression, purification, immunogenicity and protective efficacy of a recombinant nucleoside hydrolase from Leishmania donovani, a vaccine candidate for preventing cutaneous leishmaniasis. Protein Expr Purif. 2017 02; 130:129-136.
    View in: PubMed
    Score: 0.125
  4. Old World Cutaneous Leishmaniasis and Refugee Crises in the Middle East and North Africa. PLoS Negl Trop Dis. 2016 05; 10(5):e0004545.
    View in: PubMed
    Score: 0.122
  5. Combating the next lethal epidemic. Science. 2015 Apr 17; 348(6232):296-7.
    View in: PubMed
    Score: 0.113
  6. The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas. Vaccine. 2013 Jan 07; 31(3):480-6.
    View in: PubMed
    Score: 0.095
  7. A scalable and reproducible manufacturing process for Phlebotomus papatasi salivary protein PpSP15, a vaccine candidate for leishmaniasis. Protein Expr Purif. 2021 01; 177:105750.
    View in: PubMed
    Score: 0.041
  8. Status of vaccine research and development of vaccines for leishmaniasis. Vaccine. 2016 06 03; 34(26):2992-2995.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.